Overview

Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of CJ-12406 in Healthy Male Subjects

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Study objectives - To evaluate the safety, tolerability, and pharmacokinetics of escalating single oral doses of CJ-12406 in healthy male subjects. - To evaluate the pharmacodynamics of CJ-12406 after multiple oral administrations to healthy male subjects. - To evaluate the effect of food on the pharmacokinetic of a single oral dose of CJ-12406 in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
CJ HealthCare Corporation
HK inno.N Corporation